source
- Political appointee stalls Sanofi drug approval, raising concerns about FDA interferenceSTAT's D.C. Diagnosis newsletter reports that a political appointee is impeding the approval of a Sanofi drug, suggesting direct political interference at the FDA. The article notes that the appoi…
- Daraxonrasib shows 35% response rate in second‑line RAS‑mutated pancreatic cancerPhase 1/2 data from a monotherapy study of daraxonrasib in patients with RAS G12‑mutated pancreatic ductal adenocarcinoma reported an objective response rate of 35% when used as a second‑line treat…